Compare CURR & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURR | ARMP |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.6M | 125.7M |
| IPO Year | N/A | N/A |
| Metric | CURR | ARMP |
|---|---|---|
| Price | $1.46 | $6.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 224.6K | 58.2K |
| Earning Date | 11-01-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,227,053.00 | $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | $14.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $0.90 |
| 52 Week High | $4.68 | $16.34 |
| Indicator | CURR | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 35.89 | 55.35 |
| Support Level | $1.51 | $6.12 |
| Resistance Level | $1.64 | $6.37 |
| Average True Range (ATR) | 0.14 | 0.65 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 16.22 | 61.20 |
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.